Table 2.
VKDB prophylaxis strategies in various countries
| Country | Years Studied | Oral Vitamin K dosing regimen | Incidence of Late VKDB per 100,000 Infants (95% CI) |
|---|---|---|---|
| Netherlands | 1992-1994 | 1 mg at birth; 25 μg daily for 13 wk. | 0 (0 to 0.7) |
| since 2005 | 1 mg at birth; 25 μg daily for 13 wk. | 3.2 (1.2 to 6.9) | |
| Germany | 1993-1994 | 3 × 1 mg (days 1, 4-10, and 28-42) | 1.3 (0.8 to 2.0) |
| 1995-1998 | 3 × 2 mg (days 1, 4-10, and 28-42) | 0.4 (0.2 to 0.7) | |
| 1997-2000 | 3 × 2 mg (days 1, 4-10, and 28-42) | 0.8 (0.4 to 1.4) | |
| 1997-2001 | 3 × 2 mg (days 1, 4-10, and 28-42) | 0.44 (0.2 to 0.9) | |
| France | / | 2 mg weekly for 6 mo | no date available |
| Australia | 1993-1994 | 3 × 1 mg (days 1, 3-5, and 21-28) | 1.5 (0.5 to 3.6) |
| Denmark | 1992-2000 | 2 mg at birth; 1 mg weekly for 3 mo | 0 (0 to 0.9) |
| since 2000 | 2 mg im at birth | no date available | |
| Switzerland | 1995-2002 | 2 × 2 mg (h 4, day 4) | 1.2 (0 to 6.5) |
| since 2003 | 3 × 2 mg (h 4, day 4, week 4) | 0,87 (0.24 to 2.24) | |
| United Kingdom | / | 1 mg im at birth; 3 × 1 mg po (day 1, week 1, week 4) | 0.1 |
| / | 3 × 2 mg po (day 1, week 1, week 4) | 0.43 | |
| Canada | / | 1 mg im at birth | 0.37 |
| United States | / | 1 mg im at birth | no date available |
| Italy | / | various schemes | no date available |